Q1 2026 Holdings
Filed 2026-05-15 | 36 holdings | $1.7B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Relay Therapeutics Inc(RLAY) | COM | 75943R102 | $169.2M | 17,000,000 | 9.8% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $148.5M | 4,200,000 | 8.6% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $128.4M | 3,275,000 | 7.4% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $111.2M | 2,888,007 | 6.4% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $96.5M | 1,912,380 | 5.6% |
| Tyra Biosciences Inc(TYRA) | COM | 90240B106 | $94.8M | 2,475,000 | 5.5% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $85.5M | 2,696,616 | 4.9% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $85.4M | 833,600 | 4.9% |
| Amylyx Pharmaceuticals Inc(AMLX) | COM | 03237H101 | $78.5M | 5,650,000 | 4.5% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $62.5M | 750,000 | 3.6% |
| Alto Neuroscience Inc(ANRO) | COM SHS | 02157Q109 | $61.2M | 2,723,196 | 3.5% |
| Pharvaris N V(PHVS) | COM | N69605108 | $54.2M | 1,918,970 | 3.1% |
| Erasca Inc(ERAS) | COM | 29479A108 | $51.4M | 3,175,000 | 3.0% |
| Damora Therapeutics Inc(GLTO) | COM NEW | 36322Q206 | $50.2M | 1,939,000 | 2.9% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $48.0M | 825,000 | 2.8% |
| Definium Therapeutics Inc(DFTX) | COM SHS | 24477V105 | $37.8M | 2,000,000 | 2.2% |
| LB Pharmaceuticals Inc(LBRX) | COM SHS | 50180M108 | $37.0M | 1,500,000 | 2.1% |
| Eyepoint Inc(EYPT) | COM NEW | 30233G209 | $36.4M | 2,825,000 | 2.1% |
| Nurix Therapeutics Inc(NRIX) | COM | 67080M103 | $35.3M | 2,275,000 | 2.0% |
| Corvus Pharmaceuticals Inc(CRVS) | COM | 221015100 | $33.0M | 2,258,735 | 1.9% |
| Assembly Biosciences Inc(ASMB) | COM NEW | 045396207 | $27.8M | 1,000,000 | 1.6% |
| Perspective Therapeutics Inc(CATX) | COM NEW | 46489V302 | $26.4M | 6,336,782 | 1.5% |
| Soleno Therapeutics Inc(SLNO) | COM | 834203309 | $21.8M | 652,432 | 1.3% |
| Ocular Therapeutix Inc(OCUL) | COM | 67576A100 | $21.8M | 2,575,000 | 1.3% |
| Century Therapeutics Inc(IPSC) | COM | 15673T100 | $19.7M | 8,695,652 | 1.1% |
| Zura BIO LTD(ZURA) | CLASS A ORD SHS | G9TY5A101 | $19.3M | 3,250,000 | 1.1% |
| SAB Biotherapeutics Inc(SABS) | COM NEW | 78397T202 | $16.9M | 4,401,500 | 1.0% |
| Palisade BIO Inc(PALI) | COM | 696389402 | $12.6M | 7,181,062 | 0.7% |
| Karyopharm Therapeutics Inc(KPTI) | COM NEW | 48576U205 | $10.9M | 1,950,000 | 0.6% |
| Inhibikase Therapeutics Inc(IKT) | COM NEW | 45719W205 | $9.1M | 5,397,488 | 0.5% |
| An2 Therapeutics Inc(ANTX) | COM | 037326105 | $8.0M | 2,333,713 | 0.5% |
| Pepgen Inc(PEPG) | COM | 713317105 | $7.9M | 4,475,000 | 0.5% |
| Avalo Therapeutics Inc(AVTX) | COM NEW | 05338F306 | $7.2M | 483,000 | 0.4% |
| Helix Acquisition Corp III | USD CL A ORD SHS | G4444S107 | $5.1M | 500,000 | 0.3% |
| Leonabio Inc(LONA) | COM | 04746L203 | $4.8M | 464,398 | 0.3% |
| Relmada Therapeutics Inc(RLMD) | COM | 75955J402 | $4.4M | 633,901 | 0.3% |